Nyrada Inc – Updated Nyrada Investor Roadshow Presentation
Nyrada Inc (ASX: NYR) is pleased to provide shareholders and the market generally with the attached presentation ahead of a… Read more
Nyrada Inc – New Drug Offers Potential Oral Treatment for Concussion
Nyrada Inc. (ASX: NYR) released an announcement about its new lead brain injury drug candidate NYR-BI02. The new drug shows… Read more
Nyrada Half Year Results FY2022
Highlights: • Research and development costs of $1.13M as Nyrada’s lead preclinical programs advance (1H FY2021: $1.05M) • Robust cash… Read more
Nyrada Quarterly Activities Report & Appendix 4C
Highlights: • Cholesterol-Lowering Program: – Charles River Laboratories appointed to conduct safety pharmacology and toxicology studies in Nyrada’s cholesterol-lowering drug… Read more
Nyrada Receives A$1.3M R&D Tax Incentive Rebate
Nyrada Inc Brain Injury Program Update and Pathway to Phase I
This morning Nyrada provided an update on their brain injury program. The company is currently undertaking a pilot study to… Read more
NYR – Brain Injury Program Update and Pathway to Phase I
Nyrada is currently undertaking a pilot study to optimise the design of the efficacy study to evaluate its brain injury… Read more
Nyrada Inc (ASX:NYR) Cholesterol-Lowering Program Pathway To Phase I
Nyrada (ASX:NYR) has provided an update to the market regarding its cholesterol lowering drug program which is due to enter… Read more
Nyrada Inc Annual General Meeting Presentation
“Our strategy is to advance highly optimised drug candidates towards a key value inflection point , such as an efficacy… Read more